Form 8-K - Current report:
SEC Accession No. 0001558370-25-010507
Filing Date
2025-08-06
Accepted
2025-08-06 16:00:25
Documents
14
Period of Report
2025-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vygr-20250806x8k.htm   iXBRL 8-K 40813
2 EX-99.1 vygr-20250806xex99d1.htm EX-99.1 186049
3 GRAPHIC vygr-20250806xex99d1001.jpg GRAPHIC 7635
  Complete submission text file 0001558370-25-010507.txt   361885

Data Files

Seq Description Document Type Size
4 EX-101.SCH vygr-20250806.xsd EX-101.SCH 3490
5 EX-101.LAB vygr-20250806_lab.xml EX-101.LAB 15264
6 EX-101.PRE vygr-20250806_pre.xml EX-101.PRE 9839
16 EXTRACTED XBRL INSTANCE DOCUMENT vygr-20250806x8k_htm.xml XML 4617
Mailing Address 75 HAYDEN AVENUE LEXINGTON MA 02421
Business Address 75 HAYDEN AVENUE LEXINGTON MA 02421 857-259-5340
Voyager Therapeutics, Inc. (Filer) CIK: 0001640266 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37625 | Film No.: 251189335
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)